kabutan

KYORIN Pharmaceutical Co.,Ltd.(4569) Summary

4569
TSE Prime
KYORIN Pharmaceutical Co.,Ltd.
1,614
JPY
+14
(+0.88%)
Jan 29, 3:30 pm JST
10.55
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
19.3
PBR
0.68
Yield
3.53%
Margin Trading Ratio
68.88
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
1,587 JPY 10.36 USD
Previous Close Jan 28
1,600 JPY 10.48 USD
High Jan 29, 3:05 pm
1,614 JPY 10.55 USD
Low Jan 29, 9:16 am
1,575 JPY 10.28 USD
Volume
114,100
Trading Value
0.18B JPY 1.19M USD
VWAP
1600.4 JPY 10.46 USD
Minimum Trading Value
161,400 JPY 1,055 USD
Market Cap
0.10T JPY 0.64B USD
Number of Trades
428
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
372
1-Year High Mar 5, 2025
5,734
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 29,100 109,500 3.76
Jan 16, 2026 19,800 110,400 5.58
Jan 9, 2026 19,500 117,400 6.02
Dec 26, 2025 11,300 125,700 11.12
Dec 19, 2025 13,000 126,300 9.72
Company Profile
KYORIN Pharmaceutical Co., Ltd. is a mid-tier pharmaceutical company. Its main products include asthma medications and expectorants. The company also produces generic drugs and gastrointestinal medicines.
Sector
Pharmaceuticals
KYORIN Pharmaceutical Co., Ltd. primarily engages in the manufacture and sale of pharmaceuticals. The company focuses on prescription drugs such as asthma medications and expectorants, while also having a track record in generic drugs and COVID-19 detection reagents. With manufacturing and sales companies within its group, KYORIN has established an integrated business structure. The company procures some pharmaceutical raw materials from its affiliated companies. In recent years, KYORIN has undergone group restructuring, including the absorption and merger of wholly-owned subsidiaries, to improve management efficiency and accelerate decision-making processes. While adapting to changing medical needs, the company is also concentrating on developing new drugs using its proprietary drug discovery technologies.